Paragon Biosciences led by Jeff Aronin is more than just an investment firm, they support biotech companies that use technology to help people live longer and healthier lives. Their unique approach has resulted in 13 new life-saving medications, leaving many to wonder just how they do it. Paragon Biosciences has a three step process that helps them bring the most promising innovations to those in need.
First, they focus on a problem. They look at those illnesses where patient need is at an all-time high. They also consider the unavailability of treatment, because they want to provide solutions where there seems little promise from other sources (Crunchbase). In looking at these conditions, the company researches how the illnesses affect patients and what the medical community is currently doing to treat them.
Next, Paragon Biosciences builds a company around the need for a solution to the particular disease. That means investing resources in researchers, but it also means formulating a business model that will be sustainable for investors. Each company is managed by a team comprised of healthcare professionals and entrepreneurs from the biotech field. This helps to ensure researcher proposals are viable for the company to pursue.
Finally, the new company gets to work on a cure or treatment. They employ state of the art technology and the latest scientific advances to come up with new treatments for the illness that is the company’s focus. This is how Paragon brings innovative new treatments to some of the most destructive diseases facing today’s society.
Jeff Aronin is the Man Behind the Vision
Since 2010, it has been Jeff Aronin at the helm of Paragon Biosciences. He currently serves as both the company’s chairman and CEO, positions he has held for the past eight years. Prior to that, Jeff founded his own biopharmaceutical company, Ovation Pharmaceuticals Inc., in 2000. Mr. Aronin served as the president and chief executive officer of that company for nine years, before taking his position with Paragon.
Jeff’s experience has given him an edge that compliments Paragon’s vision. In addition to possessing a keen eye for financial investments and a talent for brand marketing, Aronin is experienced in developing promising strategies for business development. That collection of expertise helps Mr. Aronin recognize the most promising projects for Paragon to undertake. Under Jeff Aronin’s leadership, Paragon continues to create promising new biotech companies that promise hopeful new treatments to some of the world’s most perplexing illnesses.